Last Price
4.56
Today's Change
+0.04 (0.88%)
Day's Change
4.39 - 4.69
Trading Volume
47,705
Market Cap
14 Million
Shares Outstanding
3 Million
Avg Volume
181,958
Avg Price (50 Days)
4.57
Avg Price (200 Days)
6.07
PE Ratio
-0.11
EPS
-42.94
Earnings Announcement
07-Mar-2025
Previous Close
4.52
Open
4.39
Day's Range
4.39 - 4.69
Year Range
1.8 - 20.83
Trading Volume
47,705
1 Day Change
0.89%
5 Day Change
-1.30%
1 Month Change
-9.70%
3 Month Change
24.93%
6 Month Change
28.81%
Ytd Change
-10.59%
1 Year Change
-70.99%
3 Year Change
-98.96%
5 Year Change
-99.57%
10 Year Change
-99.57%
Max Change
-99.57%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.